Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES CLASSIFIEDS EVENTS PETS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback